GeoVax Labs (GOVX) Q4 2024 earnings summary

Executive summary

• Secured a nearly $400 million BARDA Project NextGen Award to advance the next-generation COVID-19 vaccine GEO-CM04S1, with manufacturing and clinical trial preparations underway.

• Advanced clinical programs for COVID-19, Mpox/Smallpox (GEO-MVA), and Gedeptin for oncology, with clinical evaluation for GEO-MVA expected in H2 2025 and Gedeptin phase 2 trial initiation in mid-to-late 2025.

• Strengthened manufacturing capabilities and expanded intellectual property portfolio to over 130 patents across 23 families.

• Focused on establishing global partnerships and collaborations for development, commercialization, and distribution, especially for underserved populations.

Financial highlights

• Reported $4 million in 2024 revenues from the BARDA contract, compared to zero in 2023, as the contract began mid-2024.

• Research and development expenses rose 14% year-over-year to $23.7 million, mainly due to manufacturing and BARDA-related costs.

• General and administrative expenses decreased 11% to $5.4 million, reflecting lower stock-based compensation and consulting costs.

• Net loss for 2024 was $25 million ($4.82 per share), slightly improved from $26 million ($14.29 per share) in 2023.

• Cash balance at year-end 2024 was $5.5 million, down from $6.5 million, with $24.7 million used in operations and $23.8 million raised through financing.

Outlook and guidance

• Priorities for 2025 include advancing GEO-CM04S1 under Project NextGen, progressing GEO-MVA and Gedeptin clinical programs, and achieving multiple clinical milestones.

• Data from GEO-CM04S1 booster study in healthy adults expected in H1 2025, with additional data presentations planned at major conferences.

• Clinical evaluation of GEO-MVA for Mpox/Smallpox set to begin in H2 2025.

• Expects to initiate the Gedeptin phase 2 trial in mid-to-late 2025, following resolution of manufacturing issues.